慢性乙型肝炎抗病毒治疗进展(3)
[7]Perrillo R, Hann H-W, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus[J]. Gastroenterology,2004，126(1):81-90.
[8]Kuwahara R, Kumashiro R, Inoue A, et al. Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains[J]. Dig Dis Sci,2004,49(2):300-303.
[9]Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J]. N Engl J Med,2006,354(10):1001-1010.
[10]Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med,2006,354(10):1011-1020.
[11]Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine[J]. Antimicrob Agents Chemother, 2004, 48(9):3498-3507.
[12]姚光弼,任红,王宝恩,等.恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究[J].肝脏,2005,10(1):2-4.
[13]Anna S. Lok, Fabien Zoulim, Stephen Locarnini, et al. Antiviral Drug-Resistant HBV: Standardization of Nomenclature and Assays and Recommendations for Management[J]. Hepatology, 2007,46(1):254-265.
[14]Bartholomeusz, Locarnini. Antiviraldrug resistance[J]. Seminars in Liver Disease,2006;26(2):161-170.
[15]Yim HJ, Hussain M, Liu Y, et al. Evolution of Multi-Drug Resistant Hepatitis B Virus[J]. During Sequential Therapy. Hepatology,2006,44(3):703-712.
(收稿日期：2008-09-22), 百拇医药(于金华 陈国凤)
[8]Kuwahara R, Kumashiro R, Inoue A, et al. Adefovir dipivoxil as a treatment for hepatic failure caused by lamivudine-resistant HBV strains[J]. Dig Dis Sci,2004,49(2):300-303.
[9]Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B[J]. N Engl J Med,2006,354(10):1001-1010.
[10]Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B[J]. N Engl J Med,2006,354(10):1011-1020.
[11]Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine[J]. Antimicrob Agents Chemother, 2004, 48(9):3498-3507.
[12]姚光弼,任红,王宝恩,等.恩替卡韦治疗拉米夫定失效的慢性乙型肝炎患者多中心随机双盲对照临床研究[J].肝脏,2005,10(1):2-4.
[13]Anna S. Lok, Fabien Zoulim, Stephen Locarnini, et al. Antiviral Drug-Resistant HBV: Standardization of Nomenclature and Assays and Recommendations for Management[J]. Hepatology, 2007,46(1):254-265.
[14]Bartholomeusz, Locarnini. Antiviraldrug resistance[J]. Seminars in Liver Disease,2006;26(2):161-170.
[15]Yim HJ, Hussain M, Liu Y, et al. Evolution of Multi-Drug Resistant Hepatitis B Virus[J]. During Sequential Therapy. Hepatology,2006,44(3):703-712.
(收稿日期：2008-09-22), 百拇医药(于金华 陈国凤)